Iovance Biotherapeutics, Inc.
IOVAIovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Drugs in Pipeline
7
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How IOVA's past catalysts played out
Lifileucel plus Pembrolizumab
Metastatic Melanoma
IOV-3001
Unresectable Melanoma
IOV-2001
Chronic Lymphocytic Leukemia
LN-145
Metastatic Non Small Cell Lung Cancer
Lifileucel
Endometrial Cancer
IOV-4001
Unresectable Melanoma
LN-145-S1
Squamous Cell Carcinoma of the Head and Neck
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Lifileucel plus Pembrolizumab | Phase 3 | Metastatic Melanoma | - | - |
IOV-3001 | Phase 2 | Unresectable Melanoma | - | - |
IOV-2001 | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
LN-145 | Phase 2 | Metastatic Non Small Cell Lung Cancer | - | - |
Lifileucel | Phase 2 | Endometrial Cancer | - | - |
IOV-4001 | Phase 2 | Unresectable Melanoma | - | - |
LN-145-S1 | Phase 2 | Squamous Cell Carcinoma of the Head and Neck | - | - |
Unresectable Melanoma
2 drugs in this indication
Chronic Lymphocytic Leukemia
1 drug in this indication
Metastatic Melanoma
1 drug in this indication
Squamous Cell Carcinoma of the Head and Neck
1 drug in this indication
Endometrial Cancer
1 drug in this indication
Metastatic Non Small Cell Lung Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Iovance Biotherapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 7 drug candidates in Iovance Biotherapeutics, Inc.'s (IOVA) pipeline across Phase 3, Phase 2. Its lead program is Lifileucel plus Pembrolizumab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Iovance Biotherapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Iovance Biotherapeutics, Inc. (IOVA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track IOVA biotech catalysts?→
Add IOVA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Iovance Biotherapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.